Health score, price, valuation, risk signals, and key metrics at a glance.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Strongest: Profitability (15/25); weakest: Balance Sheet & Red Flags (10/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently above its 10-quarter median.
Currently above its 13-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
FCF consistently trails net income (avg -1.1x) — earnings may be inflated by non-cash items or aggressive accounting.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
Revenue declined in 5 of the last 7 quarters — persistent contraction signals a fundamental problem.
FCF turned negative in 3 of the last 8 quarters — occasional cash consumption.
Shares outstanding increased 5.8% — significant dilution, likely from stock compensation or capital raises.
